FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas.

ABSTRACT:

Background

Molecular profiling of gliomas is vital to ensure diagnostic accuracy, inform prognosis, and identify clinical trial options for primary and recurrent tumors. This study aimed to determine the accuracy of reporting the whole arm 1p19q codeletion status from the FoundationOne platform.

Methods

Testing was performed on glioma samples as part of clinical care and analyzed up to 395 cancer-associated genes (including IDH1/2). The whole arm 1p19q codeletion status was predicted from the same assay using a custom research-use only algorithm, which was validated using 463 glioma samples with available fluorescence in-situ hybridization (FISH) data. For 519 patients with available outcomes data, progression-free and overall survival were assessed based on whole arm

SUBMITTER: Sharaf R 

PROVIDER: S-EPMC7986056 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature